Acorda Therapeutics (ACOR) Misses Q3 EPS by 22c

Acorda Therapeutics (NASDAQ: ACOR) reported Q3 EPS of $0.43, $0.22 worse than the analyst estimate of $0.65. Revenue for the quarter came in at $141.07 million versus the consensus estimate of $150.64 million.

Guidance for 2017

• The Company reiterates AMPYRA 2017 net revenue of $535-$545 million.
• R&D expenses for the full year 2017 are expected to be $160-$170 million. This guidance is a non-GAAP projection that excludes share-based compensation and restructuring costs, as more fully described below under “Non-GAAP Financial Measures.”
• The Company is reducing its SG&A expense guidance for the full year 2017 from $170-$180 million to $160-$170 million. This guidance is a non-GAAP projection that excludes share-based compensation and restructuring costs, as more fully described below under “Non-GAAPFinancial Measures.”
• The Company expects to be cash flow positive in 2017, with a projected year-end cash balance in excess of $200 million.

For earnings history and earnings-related data on Acorda Therapeutics (ACOR) click here.

You May Also Be Interested In

• BJ's Wholesale Club (BJ) Tops Q2 EPS by 19c, Beats on Revenue; Offers FY27 EPS Guidance
• Opera Limited (OPRA) Misses Q2 EPS by 1c ; Offers Guidance
• Deere & Co. (DE) Tops Q3 EPS by 41c, raises guidance